Outlook Therapeutics announces positive topline results from its NORSE [--] Phase [--] trial for bevacizumab (BYAAY) for wet AMD. The company plans to submit a Biologics License Application (BLA) to the FDA in the second half of [----].
Outlook Therapeutics is a biopharmaceutical company focused on developing treatments for ophthalmic conditions.
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing